Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 32.58 Million USD | -66.05% |
| 2022 | 95.98 Million USD | 22.24% |
| 2021 | 78.51 Million USD | 66.51% |
| 2020 | 47.15 Million USD | 52.2% |
| 2019 | 30.98 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.1 Million USD | 19.29% |
| 2024 Q1 | 5.12 Million USD | 10.44% |
| 2023 Q3 | 3.78 Million USD | -58.36% |
| 2023 FY | 32.58 Million USD | -66.05% |
| 2023 Q4 | 4.63 Million USD | 22.64% |
| 2023 Q2 | 9.08 Million USD | -50.12% |
| 2023 Q1 | 18.2 Million USD | -33.84% |
| 2022 Q2 | 22.08 Million USD | -11.42% |
| 2022 Q1 | 24.93 Million USD | 25.5% |
| 2022 FY | 95.98 Million USD | 22.24% |
| 2022 Q4 | 27.51 Million USD | 28.33% |
| 2022 Q3 | 21.44 Million USD | -2.92% |
| 2021 FY | 78.51 Million USD | 66.51% |
| 2021 Q4 | 19.86 Million USD | -6.62% |
| 2021 Q3 | 21.27 Million USD | 7.21% |
| 2021 Q1 | 17.52 Million USD | 17.32% |
| 2021 Q2 | 19.84 Million USD | 13.23% |
| 2020 FY | 47.15 Million USD | 52.2% |
| 2020 Q4 | 14.93 Million USD | 26.05% |
| 2020 Q3 | 11.85 Million USD | 10.67% |
| 2020 Q2 | 10.7 Million USD | 10.92% |
| 2020 Q1 | 9.65 Million USD | 0.0% |
| 2019 FY | 30.98 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -4828.527% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -251.629% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -8.655% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 51.466% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -105.7% |
| Better Therapeutics, Inc. | 38.26 Million USD | 14.827% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 19.907% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -162.969% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 3.708% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 5.317% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 69.955% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -3182.504% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 30.589% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -2582.911% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -63.441% |
| Molecular Templates, Inc. | 63.09 Million USD | 48.346% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -133.921% |
| NexImmune, Inc. | 28.16 Million USD | -15.697% |
| Orgenesis Inc. | 45.75 Million USD | 28.778% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -27.067% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -44289.506% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -101.849% |
| Scopus BioPharma Inc. | 11.71 Million USD | -178.185% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 91.925% |
| Statera Biopharma, Inc. | 28.82 Million USD | -13.04% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -72.164% |
| Trevena, Inc. | 38.41 Million USD | 15.162% |
| Vaxxinity, Inc. | 56.05 Million USD | 41.858% |
| Vaccinex, Inc. | 23.45 Million USD | -38.943% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -3012.673% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 35.713% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -347.982% |